SECsense Logo

Intellia Therapeutics 8-K Filing: Key Insights & Stock Info for February 2025

$NTLA
Form 8-K
Filed on: 2025-02-21
Source
Intellia Therapeutics 8-K Filing: Key Insights & Stock Info for February 2025

Based on the provided section of the financial report, here are the key extracted insights:

  1. Entity Information:
  • Company Name: Intellia Therapeutics, Inc.
  • CIK Number: 0001652130
  • SEC File Number: 001-37766
  • EIN: 36-4785571
  • Address: 40 Erie Street, Suite 130, Cambridge, MA 02139
  • Contact Number: (857) 285-6200
  1. Filing Type:
  • The report is an 8-K filing, which typically reports significant events that shareholders should know.
  1. Date of Filing:
  • The filing date is February 18, 2025.
  1. Stock Information:
  • Common Stock: The company has common stock with a par value of $0.0001.
  • Ticker Symbol: NTLA
  • Stock Exchange: The stock is listed on NASDAQ.
  1. Period Covered:
  • The context indicates that the reporting period starts and ends on February 18, 2025, suggesting it may cover a specific event or announcement made on that date.

Summary:

This section of the financial report provides essential details about Intellia Therapeutics, Inc., including its contact information, SEC filing type, stock details, and the timing of the report. The 8-K filing indicates that there may be significant information disclosed relevant to investors or stakeholders on the specified date.